Howard & Howard Attorneys PLLC
Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
Cayman Chemical Company, Incorporated
Stephen Douglas Fred Lawrence Kirk Lang Gregory W. Pil Heui James Bernard
Barrett Ciske Olson Endres Lee Kramer